- Atlas
- Medicine & Health
- Pharmacokinetics
Pharmacokinetics
Pharmacokinetics is the study of what the body does to a drug: how a dose is absorbed, where it distributes, how it is chemically changed, and how it is finally removed.
8 frameworks, from 1930 to today · Pharmacology · Medicine & Health
- Compartmental pharmacokinetic modeling 1930-Present
- Bioavailability and first-pass metabolism framework 1950-Present
- Physiological clearance and volume-of-distribution framework 1950-Present
- Nonlinear (saturable) kinetics 1960-Present
- Therapeutic drug monitoring 1965-Present
- Population pharmacokinetics 1975-Present
- Pharmacogenomic pharmacokinetics 1990-Present
- Physiologically based pharmacokinetic modelling 1990-Present
Overview
Pharmacokinetics is the study of what the body does to a drug: how a dose is absorbed, where it distributes, how it is chemically changed, and how it is finally removed1. Its practitioners ask a deceptively simple set of questions—how much drug reaches the blood, how long it stays there, and what determines its concentration at the moment it matters1. The field matters because the same dose that cures one patient can poison another, and the difference often lies not in the drug's action but in the body's handling of it. Where pharmacodynamics asks what a drug does to the body, pharmacokinetics asks what the body does to the drug, and the two together turn a vague notion of "dose" into a measurable, predictable quantity12.
From Folk Dosing to Measurable Concentration
For most of medical history, dosing was empirical. Physicians adjusted remedies by observation of effect and by tradition, with no way to know how much active substance was present in the blood. The intellectual groundwork for a quantitative approach came from chemistry and physiology in the nineteenth century. The isolation of active principles—morphine from opium in the early 1800s, for instance—made it possible to speak of a known quantity of a substance rather than an uncertain preparation. Physiologists meanwhile began to study how substances move through living organisms, and the idea took hold that a drug's effect depends on its concentration at the site of action, not merely on the amount swallowed.
The decisive shift came in the early twentieth century, when pharmacologists began to measure drug concentrations in blood and tissue and to describe their rise and fall over time. The word "pharmacokinetics" itself entered use in this period, and the field's central insight crystallized: the body treats a drug as a substance to be transported, distributed, metabolized, and excreted, and each of these processes follows patterns that can be described mathematically.
The Compartmental Model and the Language of Half-Life
The first great organizing idea was the compartmental model. Rather than tracking a drug through every organ, pharmacologists treated the body as one or a few well-mixed "compartments"—abstract volumes in which the drug is assumed to distribute evenly1. A one-compartment model treats the whole body as a single pool; a two-compartment model adds a peripheral pool that the drug enters and leaves more slowly1. The appeal was practical: a handful of parameters could describe a concentration–time curve, and the most famous of these, the half-life (the time for blood concentration to fall by half), became a standard measure of how long a drug persists.
The mathematics of this approach was formalized in the 1960s and 1970s, notably in the work of pharmacologists who adapted chemical kinetics to living systems. The compartmental framework made it possible to design dosing regimens—how often to give a drug, and how large a dose—so that concentration stayed within a therapeutic window. It also introduced the idea of steady state, the point at which drug entering the body balances drug leaving it, so that concentrations stabilize during repeated dosing1.
Clearance, Bioavailability, and the First-Pass Problem
A second wave of concepts gave the field its physiological vocabulary. Clearance is the volume of blood or plasma from which a drug is completely removed per unit time; it captures the combined efficiency of the liver, kidneys, and other eliminating organs. Volume of distribution describes how widely a drug spreads through the body relative to its concentration in plasma13. Together, clearance and volume of distribution determine half-life, and this relationship—half-life proportional to volume of distribution divided by clearance—became a cornerstone of the field1.
The bioavailability and first-pass framework addressed a problem that had long puzzled clinicians: why does the same amount of a drug given by mouth produce far less effect than when injected? The answer lay in incomplete absorption from the gut and in first-pass metabolism—the liver's removal of a portion of the drug before it ever reaches the general circulation45. Measuring bioavailability (the fraction of a dose that reaches the bloodstream unchanged) became essential for comparing formulations and routes of administration14. This framework, developed through the mid-twentieth century and refined as oral drug therapy expanded, explained why some drugs are useless by mouth and why dosing must differ by route.
Nonlinear Kinetics: When the Body's Machinery Saturates
The early models assumed that elimination processes work proportionally—double the concentration, double the rate of removal1. But some drugs showed a different pattern: as concentration rose, the rate of elimination stopped keeping pace, and small dose increases produced disproportionately large rises in blood concentration1. This is nonlinear, or saturable, kinetics, and it reflects the finite capacity of the enzymes and transporters that handle a drug1. The classic demonstration came with drugs such as phenytoin, whose metabolism saturates within the therapeutic range, so that a modest dose increase can push concentrations into toxic territory. Recognizing saturation changed clinical practice: for such drugs, dosing must be individualized and monitored, because the relationship between dose and concentration is no longer predictable by simple proportion1.
Therapeutic Drug Monitoring
The ability to measure drug concentrations in blood made possible therapeutic drug monitoring—the practice of adjusting doses by measuring plasma levels rather than relying on clinical impression alone6. It became established for drugs with narrow therapeutic windows, where the gap between effective and toxic concentrations is small: lithium for bipolar disorder, digoxin for heart failure, aminoglycoside antibiotics, and the immunosuppressant cyclosporine are standard examples17. Monitoring required reliable assays and an understanding of when to sample—at what point in the dosing interval the concentration is meaningful6. It turned pharmacokinetic theory into a bedside tool and made the case that individual patients differ enough to warrant measurement rather than assumption1.
Population Pharmacokinetics and the Individual Patient
A further problem emerged: patients are not identical, and a dosing regimen built for an average adult may fail in a child, an elderly patient, or someone with kidney disease1. Population pharmacokinetics addressed this by studying concentration data from many patients at once, using statistical models to separate the typical behavior of a drug from the variability between individuals and within the same individual over time. The approach, developed from the 1970s onward and greatly aided by computing power, identifies which patient characteristics—weight, age, kidney function, genetic makeup—explain differences in clearance and volume of distribution. It made possible Bayesian dose individualization, in which a patient's own measured concentrations are used to refine their predicted dosing. This is now central to clinical pharmacology, especially in specialized settings such as neonatal intensive care and transplant medicine.
Physiologically Based Modeling: Building the Body in Silico
Compartmental models are abstract; physiologically based pharmacokinetic (PBPK) modeling instead represents the body as a set of real organs connected by blood flow, each with its own volume and permeability. The approach has roots in the mid-twentieth century, when physiologists and pharmacologists began constructing flow-based descriptions of drug distribution, but it matured with computing power in the 1990s and 2000s. PBPK models can predict concentrations in specific tissues—the brain, the fetus, a tumor—and can be adapted across species and populations. Regulators now accept PBPK analyses in some drug development contexts, for instance to predict drug–drug interactions or to support dosing in populations that are hard to study directly, such as pregnant women or children.
Molecular and Pharmacogenomic Pharmacokinetics
The most recent layer of the field looks at the molecules that handle drugs. Drug-metabolizing enzymes—the cytochrome P450 family prominent among them—and drug transporters determine how fast a drug is cleared and where it goes. The discovery that these proteins vary between people, often because of inherited genetic differences, founded pharmacogenomic pharmacokinetics: the study of how a person's genes shape their handling of a drug. The classic example is the enzyme CYP2D6, whose activity varies widely across individuals and populations, affecting drugs from codeine to certain antidepressants. Genotyping can now predict whether a patient is a poor or rapid metabolizer and guide dose selection. This work connects pharmacokinetics to the broader field of pharmacogenomics and represents the field's move from describing average behavior to predicting individual behavior from molecular information8.
The Present: Model-Informed, Individualized, and Still Uncertain
Today's pharmacokinetics is model-informed and increasingly individualized. Compartmental analysis remains the everyday language of the clinic, while population approaches and PBPK modeling handle complexity and prediction1. Therapeutic drug monitoring and pharmacogenomic testing put individualization into practice for selected drugs6. The open questions are substantial: how to predict pharmacokinetics in populations rarely studied, how to integrate genetic, physiological, and environmental sources of variability into usable models, and how to make monitoring and genotyping practical at scale. The field's history is a story of learning to measure—first the drug in the blood, then the body's handling of it, then the molecules and genes behind that handling—and each measurement made the next question sharper.
References
- Pharmacokinetics (introduction, ADME, Compartmental analysis, Single-compartment model, Two-compartment model, Metrics, Bioavailability, Multi-compartment models, Clinical pharmacokinetics, Population pharmacokinetics, Modeling), Wikipedia
- Pharmacodynamics, Wikipedia
- Volume of distribution, Wikipedia
- Bioavailability, Wikipedia
- First pass effect, Wikipedia
- Therapeutic drug monitoring, Wikipedia
- Therapeutic index, Wikipedia
- Pharmacogenomics, Wikipedia
The frameworks of Pharmacokinetics
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1930-Present
Compartmental pharmacokinetic modeling
How does blood concentration change over time after a dose?
- 1950-Present
Bioavailability and first-pass metabolism framework
How much of a dose actually reaches the bloodstream?
- 1950-Present
Physiological clearance and volume-of-distribution framework
What determines how fast and how widely a drug is removed?
- 1960-Present
Nonlinear (saturable) kinetics
Why do small dose increases sometimes cause huge concentration jumps?
- 1965-Present
Therapeutic drug monitoring
When should a patient's drug level be measured and acted on?
- 1975-Present
Population pharmacokinetics
Why do patients given the same dose differ so much?
- 1990-Present
Pharmacogenomic pharmacokinetics
How do inherited genes change a person's handling of a drug?
- 1990-Present
Physiologically based pharmacokinetic modelling
How can tissue drug concentrations be predicted without measuring them?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Population pharmacokinetics grew out of Compartmental pharmacokinetic modeling
Population pharmacokinetics generalized the compartmental model by adding statistical models of between-subject and residual variability to the same structural parameters. The nonlinear mixed-effects approach of Sheiner and Beal treated individual curves as draws from a population distribution.
Carried by Lewis Sheiner; Stuart Beal.
Bioavailability and first-pass metabolism framework grew out of Compartmental pharmacokinetic modeling
Compartmental analysis supplied the concentration–time curves and area-under-the-curve arithmetic that bioavailability measurement depends on; comparing oral and intravenous curves to compute the absorbed fraction was built directly on compartmental methods.
Physiological clearance and volume-of-distribution framework grew out of Compartmental pharmacokinetic modeling
Clearance and volume of distribution were defined so as to make the compartmental half-life relation explicit: half-life equals volume of distribution divided by clearance. The physiological vocabulary was grafted onto the compartmental parameters rather than replacing them.
Nonlinear (saturable) kinetics grew out of Compartmental pharmacokinetic modeling
Saturable kinetics arose by rejecting the first-order assumption built into compartmental models, showing that for drugs like phenytoin elimination rate does not scale with concentration. The Michaelis–Menten treatment was offered as a correction to the linear compartmental picture.
Therapeutic drug monitoring influenced by Compartmental pharmacokinetic modeling
Dosing-interval reasoning and steady-state concepts from compartmental modeling told clinicians when a plasma sample would be interpretable, which made routine monitoring practicable. Monitoring applied compartmental predictions at the bedside.
Physiologically based pharmacokinetic modelling grew out of Compartmental pharmacokinetic modeling
PBPK was framed as a corrective to abstract lumped compartments, substituting real organ volumes and flows so that tissue concentrations could be predicted. The whole-body flow models of the mid-twentieth century were revived against the compartmental tradition.
Population pharmacokinetics influenced by Physiological clearance and volume-of-distribution framework
Population models sought to explain variability in exactly the physiological parameters of clearance and volume of distribution, and to relate them to covariates such as weight and renal function.
Pharmacogenomic pharmacokinetics influenced by Physiological clearance and volume-of-distribution framework
Pharmacogenomics explained interindividual variation in clearance by attributing it to inherited differences in metabolizing enzymes and transporters, using the clearance framework as its measuring stick.
Physiologically based pharmacokinetic modelling grew out of Physiological clearance and volume-of-distribution framework
PBPK modeling took the clearance and organ-perfusion view of drug disposition and made each organ an explicit compartment with its own blood flow and volume, replacing lumped parameters with anatomical ones.
Therapeutic drug monitoring influenced by Nonlinear (saturable) kinetics
The demonstration that phenytoin and similar drugs show disproportionate concentration rises with dose gave the strongest clinical argument for measuring plasma levels and adjusting doses individually.
Population pharmacokinetics influenced by Therapeutic drug monitoring
Routine plasma level measurements in patients generated the sparse, unbalanced concentration data that population methods were built to analyze, and Bayesian dose individualization grew out of monitoring practice.
Carried by Lewis Sheiner.
Pharmacogenomic pharmacokinetics influenced by Population pharmacokinetics
Population pharmacokinetic covariate analysis identified genotype as one of the patient characteristics explaining variability in clearance, giving pharmacogenomic pharmacokinetics its quantitative footing.
Nonlinear (saturable) kinetics influenced by Physiological clearance and volume-of-distribution framework
The clearance framework made it possible to state precisely what saturates: clearance falls as eliminating enzymes approach capacity, so dose–concentration relations become nonlinear. Saturation was described as concentration-dependent clearance.
Physiologically based pharmacokinetic modelling influenced by Population pharmacokinetics
Population methods supplied the variability and covariate structure that PBPK models later incorporated to scale predictions across ages, genotypes and disease states.
Beyond the field
Where Pharmacokinetics's ideas came from in other fields, and what they led to there: the strongest 12 of 46 links.
Compartmental pharmacokinetic modeling led to Physiologically based pharmacokinetic modelling in Pharmacometrics
PBPK modelling is a refinement of compartmental pharmacokinetic modelling, replacing abstract compartments with anatomically defined organ compartments connected by blood flow.
Compartmental pharmacokinetic modeling influenced Population pharmacokinetics and Bayesian individualization in Clinical Pharmacology
Compartmental pharmacokinetic modeling supplied the differential-equation structures that population methods estimate with mixed-effects statistics. The population approach is a statistical extension of these deterministic models to many individuals at once.
Carried by Lewis B. Sheiner; Stuart L. Beal.
Compartmental pharmacokinetic modeling influenced PKPD model in Pharmacometrics
Compartmental pharmacokinetic modelling supplied the differential-equation structure and rate constants that PKPD models use for the concentration side before attaching an effect compartment or Emax link.
Population pharmacokinetics influenced Bayesian pharmacometrics in Pharmacometrics
Population pharmacokinetic models and their nonlinear mixed-effects estimation are the object to which Bayesian pharmacometrics applies Bayesian estimation and prior information.
Population pharmacokinetics led to Model-Informed Precision Dosing in Pharmacometrics
Population pharmacokinetics provided the structural and variability models on which model-informed precision dosing bases its individualized dose predictions.
Carried by Population pharmacokinetics.
Population pharmacokinetics influenced Model-informed drug development in Pharmacometrics
Population pharmacokinetic modelling is the methodological backbone of model-informed drug development, providing the exposure models used to link dose to response and to support dose selection. The later framework generalizes population PK into an integrated development decision tool.
Population pharmacokinetics led to Nonlinear mixed-effects modeling in Pharmacometrics
Population pharmacokinetics required methods to estimate fixed and random effects from sparse data, and nonlinear mixed-effects modeling was created to fill that need.
Carried by Population pharmacokinetics.
Population pharmacokinetics influenced Clinical trial simulation in Pharmacometrics
Population pharmacokinetic models, with their estimates of between-subject and residual variability, are the core generative models in clinical trial simulation.
Pharmacogenomic pharmacokinetics grew out of Classical Pharmacogenetics in Pharmacogenomics
Classical pharmacogenetics, founded on inherited enzyme polymorphisms such as pseudocholinesterase and acetylation status, supplied the concepts and case material that pharmacogenomic pharmacokinetics generalised to genome-wide markers and routine dosing.
Carried by Friedrich Vogel; Werner Kalow.
Physiologically based pharmacokinetic modelling grew out of Pharmacokinetics in Pharmacology
The pharmacokinetics entry under Pharmacology is the parent discipline from which physiologically based modelling branched, keeping its aim of predicting concentration-time courses while adding physiological structure.
Physiologically based pharmacokinetic modelling grew out of Pharmacokinetics in Pharmacology
Physiologically based pharmacokinetic modelling grew directly out of classical pharmacokinetics, replacing lumped compartments with organ-level blood-flow and partition-coefficient descriptions of drug disposition.
Physiologically based pharmacokinetic modelling grew out of Compartmental pharmacokinetics in Pharmacometrics
Compartmental pharmacokinetics provided the rate constants, clearance concepts and parameter-estimation methods that physiologically based modelling replaced with anatomically explicit organ compartments while retaining the same mass-balance mathematics.

Pharmacokinetics is a planet in Nousfarer
Its city has a tower for each of these 8 frameworks. Land, walk in, and climb one concept at a time.
Land on PharmacokineticsRelated fields
Fields its ideas are linked to
- Pharmacometrics 23 links
- Pharmacology 6 links
- Translational Pharmacology 4 links
- Pharmacogenomics 3 links
- Aquatic Nutrition 1 link
- Biochemistry 1 link
- Reaction Engineering 1 link
- Biogeochemistry 1 link
- Nephrology 1 link
- Clinical Pharmacology 1 link
- Receptor Theory And Signal Transduction 1 link
- Clinical Pharmacy 1 link
More in Pharmacology
- Clinical Pharmacology
- Drug Discovery
- Pharmacodynamics
- Pharmacogenomics
- Pharmacology
- Pharmacometrics
- Pharmacovigilance
- Receptor Theory And Signal Transduction
- Toxicology
- Translational Pharmacology
See where Pharmacokinetics sits on the Map of Human Knowledge